secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-103520
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Q2 net loss narrows to $17.4M; obicetrapib data published in NEJM and Lancet
--------------------------------------------------------------------------------

- Cash, equivalents and securities $783.3M at June 30, 2025, down from $834.2M at Dec 31, 2024.
- Revenue $19.1M (vs $2.3M YoY) driven by $16.1M Menarini development milestone.
- R&D expenses $27.5M (vs $38.4M YoY) on lower clinical costs; SG&A $27.3M (vs $16.5M YoY) on pre-commercial investment.
- Net loss $17.4M compared to $39.0M in Q2 2024; improvement from higher revenue and lower R&D.
- EMA marketing authorisation application on track for 2H25; BROADWAY AD biomarker data showed significant p-tau217 reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025103520/0000950170-25-103520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025103520/nams-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer